Vicapsys Life Sciences, Inc.
OOTC:VICPCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Federico Luis Pier
- Full Time Employees
- 2
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Centro de Distribución Amelia Suwanee PR United States 00969
- IPO Date
- Jul 11, 2001
- CIK
- 0001468639
- Website
- vicapsys.com
- Similar Companies
- Business
- Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc. (VICP) is a clinical-stage biotechnology company that develops and commercializes proprietary CXCL12-based therapies to create localized immune protection for cells, tissues, organs, and devices, targeting chronic inflammatory conditions without systemic immunosuppression. The company offers VICAPSYN, an alginate-encapsulated product line for transplantation therapies including stem-cell derived beta-islet cells to treat Type 1 diabetes by enabling long-term survival of transplanted allogeneic human islet cells in the peritoneal cavity; and ViBrin, a non-cellular CXCL12 formulation complexed into bioabsorbable polymers applied post-debridement to accelerate healing of diabetic foot ulcers through inflammation inhibition, stem cell recruitment, and angiogenesis, or to prevent post-surgical peritoneal adhesions by blocking fibrosis and immune responses at incision sites. Founded in 1997 and headquartered in Suwanee, Georgia, Vicapsys Life Sciences operates primarily in the United States with a global development focus, leveraging technology exclusively licensed from Massachusetts General Hospital in 2013 and supported by eight patent families covering cellular and non-cellular applications; the company employs a small team of two and trades on OTC Markets. Recent advancements include ongoing non-human primate studies demonstrating six-month functionality of CXCL12-protected stem cell-derived beta cells in healthy models with diabetic primate trials in progress, alongside preclinical validation of ViBrin for wound healing and adhesion prevention in validated animal models. In 2022, the company appointed three new board members—Richard Rosenblum, Dr. Colleen Delaney, and Charles Farrahar—and named Federico Pier as permanent CEO, following platform milestones like reduced transplant rejection in primate studies initiated in 2016-2017; no major acquisitions, funding rounds, or partnerships have been announced in the last two years.
Company News
Housekeeping Starts with Branding: Vicapsys Life Sciences Adopts New Corporate Identity Developed by FutureBrand for Vicapsys and Its Stateline Subsidiary
Vicapsys Life Sciences Announces Advisory Board Following Completion of Stateline Merger
RETRANSMISSION: Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist(R), Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal and Underserved Markets
Vicapsys Life Sciences Completes Reverse Merger with Stateline Distributors of Puerto Rico and Signs Definitive Agreement to Acquire NitroMist(R), Creating a Vertically Integrated Pharmaceutical Manufacturing and Distribution Platform Serving Federal, Tribal and Underserved Markets